Mass spectrometry-based serum proteomics for biomarker discovery and validation

Methods in Molecular Biology

Volumn 1619, Issue , 2017, Pages 451-466

  Bhosale, Santosh D ^a   Moulder, Robert ^a   Kouvonen, Petri ^a   Lahesmaa, Riitta ^a   Goodlett, David R ^a,b  

^a UNIVERSITY OF TURKU   (Finland)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

Label free quantification; Mass spectrometry; Proteomics; Selected reaction monitoring; Serum plasma

Indexed keywords

BIOLOGICAL MARKER; PLASMA PROTEIN; PROTEOME;

ANTIBODY AFFINITY; CONTROLLED STUDY; DILUTION; MASS SPECTROMETRY; PROTEOMICS; VALIDATION STUDY; WORKFLOW; HUMAN; LIQUID CHROMATOGRAPHY; PROCEDURES; REPRODUCIBILITY; STATISTICS;

BIOMARKERS; BLOOD PROTEINS; CHROMATOGRAPHY, LIQUID; HUMANS; MASS SPECTROMETRY; PROTEOME; PROTEOMICS; REPRODUCIBILITY OF RESULTS; STATISTICS AS TOPIC; WORKFLOW;

EID: 85021720400     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-7057-5_31     Document Type: Chapter

References (27)

1. Veenstra TD, Conrads TP, Hood BL, Avellino AM, Ellenbogen RG, Morrison RS (2005) Biomarkers: mining the biofluid proteome. Mol Cell Proteomics 4:409–418
2. Lyons TJ, Basu A (2012) Biomarkers in diabetes: hemoglobin A1c, vascular and tissue markers. Transl Res 159:303–312
3. Crutchfield CA, Thomas SN, Sokoll LJ, Chan DW (2016) Advances in mass spectrometry-based clinical biomarker discovery. Clin Proteomics 13:1
4. Dayon L, Kussmann M (2013) Proteomics of human plasma: a critical comparison of analytical workflows in terms of effort, throughput and outcome. EuPA Open Proteom 1:8–16
5. Rifai N, Gillette MA, Carr SA (2006) Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 24:971–983
6. Surinova S, Schiess R, Hüttenhain R, Cerciello F, Wollscheid B, Aebersold R (2011) On the development of plasma protein biomarkers. J Proteome Res 10:5–16
7. Picotti P, Aebersold R (2012) Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions. Nat Methods 9:555–566
8. Lange V, Picotti P, Domon B, Aebersold R (2008) Selected reaction monitoring for quantitative proteomics: a tutorial. Mol Syst Biol 4:222
9. Escher C, Reiter L, MacLean B, Ossola R, Herzog F, Chilton J, MacCoss MJ, Rinner O (2012) Using iRT, a normalized retention time for more targeted measurement of peptides. Proteomics 12(8):1111–1121
10. Issaq HJ, Xiao Z, Veenstra TD (2007) Serum and plasma proteomics. Chem Rev 107(8): 3601–3620
11. Tu C, Rudnick PA, Martinez MY, Cheek KL, Stein SE, Slebos RJ, Liebler DC (2010) Depletion of abundant plasma proteins and limitations of plasma proteomics. J Proteome Res 9(10):4982–4991
12. Geyer PE, Kulak NA, Pichler G, Holdt LM, Teupser D, Mann M (2016) Plasma proteome profiling to assess human health and disease. Cell Syst 2(3):185–195
13. Ahmed N, Barker G, Oliva K, Garfin D, Talmadge K, Georgiou H, Quinn M, Rice G (2003) An approach to remove albumin for the proteomic analysis of low abundance biomarkers in human serum. Proteomics 3(10):1980–1987
14. Smith MP, Wood SL, Zougman A, Ho JT, Peng J, Jackson D, Cairns DA, Lewington AJ, Selby PJ, Banks RE (2011) A systematic analysis of the effects of increasing degrees of serum immunodepletion in terms of depth of coverage and other key aspects in top-down and bottom-up proteomic analyses. Proteomics 11(11):2222–2235
15. Moulder R, Goo YA, Goodlett DR (2016) Label-free quantitation for clinical proteomics. Methods Mol Biol 1410:65–76
16. Cox J, Mann M (2008) MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 26:1367–1372
17. Megger DA, Bracht T, Kohl M, Ahrens M, Naboulsi W, Weber F, Hoffmann AC, Stephan C, Kuhlmann K, Eisenacher M, Schlaak JF, Baba HA, Meyer HE, Sitek B (2013) Proteomic differences between hepatocellular carcinoma and nontumorous liver tissue investigated by a combined gel-based and label-free quantitative proteomics study. Mol Cell Proteomics 12:2006–2020
18. Cox J, Neuhauser N, Michalski A, Scheltema RA, Olsen JV, Mann M (2011) Andromeda: a peptide search engine integrated into the MaxQuant environment. J Proteome Res 10:794–1805
19. Tyanova S, Temu T, Sinitcyn P, Carlson A, Hein MY, Geiger T, Mann M, Cox J (2016) The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat Methods 13(9):731–740
20. Tyanova S, Mann M, Cox J (2014) MaxQuant for in-depth analysis of large SILAC datasets. Methods Mol Biol 1188:351–364
21. Cox J, Hein MY, Luber CA, Paron I, Nagaraj N, Mann M (2014) Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol Cell Proteomics 13:2513–2526
22. R Development Core Team (2011) R: a language and environment for statistical computing, Vienna, Austria
23. IBM Corp. Released 2013. IBM SPSS statistics for windows version 22.0. IBM Corp., Armonk, NY
24. MacLean B, Tomazela DM, Shulman N, Chambers M, Finney GL, Frewen B, Kern R, Tabb DL, Liebler DC, MacCoss MJ (2010) Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 26:966–968
25. Brusniak MK, Kwok S, Christiansen M, Campbell D, Reiter L, Picotti P, Kusebauch U, Ramos H, Deutsch EW, Chen J, Moritz RL, Aebersold R (2011) ATAQS: A computational software tool for high throughput transition optimization and validation for selected reaction monitoring mass spectrometry. BMC Bioinformatics 12:78
26. Teleman J, Karlsson C, Waldemarson S, Hansson K, James P, Malmström J, Levander F (2012) Automated selected reaction monitoring software for accurate label-free protein quantification. J Proteome Res 11(7):3766–3773
27. Aiyetan P, Thomas SN, Zhang Z, Zhang H (2015) MRMPlus: an open source quality control and assessment tool for SRM/MRM assay development. BMC Bioinformatics 16:411